ImmunityBio, Inc.IBRXNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank25
Studio
Year-over-Year Change

Cash generated from core business operations

Latest
$-304.94M
↓ 42% vs avg
Percentile
P25
Within normal range
Streak
1 yr
Consecutive growthContracting
Average
$-214.94M
Historical baseline
PeriodValueYoY Change
TTM$-304.94M+22.1%
2024$-391.24M-6.7%
2023$-366.76M-8.7%
2022$-337.51M-23.0%
2021$-274.42M-59.8%
2020$-171.72M-12.9%
2019$-152.11M-140.0%
2018$-63.38M-29.9%
2017$-48.78M-26.4%
2016$-38.59M-